Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide.
Despite the availability of over 20 antiseizure drugs (ASDs) for symptomatic treatment of …

The blood-brain barrier (BBB) plays a key role in maintaining the specialized
microenvironment of the central nervous system (CNS), and enabling communication with …

Epilepsy is a common neurological disorder that affects over 70 million people worldwide.
Despite the recent introduction of new antiseizure drugs (ASDs), about one-third of patients …

Central nervous system (CNS) barriers predominantly mediate the immune-privileged status
of the brain, and are also important regulators of neuroimmune communication. It is …

The blood-brain barrier (BBB) contributes to brain homeostasis by protecting the brain from
potentially harmful endogenous and exogenous substances. BBB active drug efflux …

Resistance to drug treatment is an important hurdle in the therapy of many brain disorders,
including brain cancer, epilepsy, schizophrenia, depression and infection of the brain with …

Neuroimmunology is concerned with the relations between the central nervous and immune
systems and with the mechanisms that drive those relations. The blood-brain barrier (BBB) …

Epilepsy, a common multifactorial neurological disease, affects about 69 million people
worldwide constituting nearly 1% of the world population. Despite decades of extensive …

The blood–brain barrier (BBB) serves as a protective mechanism for the brain by preventing
entry of potentially harmful substances from free access to the central nervous system …

Drug‐resistant epilepsy with uncontrolled severe seizures despite state‐of‐the‐art medical
treatment continues to be a major clinical problem for up to one in three patients with …